Somatostatin pp 293-302 | Cite as

Effect of a Long-Acting Somatostatin Analog (Sms 201–995) on Glucose Homeostasis in Type I Diabetes and in Acromegaly

  • E. del Pozo
  • S. W. J. Lamberts
  • C. Sieber
  • A. Gomez-Pan
Part of the Serono Symposia, USA book series (SERONOSYMP)


Recently, Bauer et al. (1) have reported the synthesis of an octapeptide SMS 201–995 (DPhe-Cys-Phe-DTrp-Lys-Thr-Cys-Thr-ol), found in animal experiments to be about 45 times more potent than native somatostatin (SRIF).


Growth Hormone Acromegalic Patient Continuous Subcutaneous Insulin Infusion Artificial Pancreas Blood Glucose Profile 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bauer W, Briner U, Doepfner W, et al. SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31: 1133.PubMedCrossRefGoogle Scholar
  2. 2.
    del Pozo E, Rutz K. Pharmacological properties and effect on glucose homeostasis of a somatostatin derivative (SMS 201–995): studies in humans. In: Ludecke D, Tolis G, eds. Growth factors and acromegaly. New York: Raven Press (in press).Google Scholar
  3. 3.
    del Pozo E, Neufeld M, Schluter K, et al. Endocrine profile of a long-acting somatostatin derivate SMS 201–995. Study in normal volunteers following subcutaneous administration. Acta Endocrinol 1986; 11: 433.Google Scholar
  4. 4.
    Plewe G, Beyer J, Krause U, Neufeld M, del Pozo E. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201–995 in acromegaly. Lancet 1984; 2: 782.PubMedCrossRefGoogle Scholar
  5. 5.
    Lamberts SWJ, Oosterom R, Neufeld M, del Pozo E. The somatostatin analog SMS 201–995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 1985; 60: 1161.PubMedCrossRefGoogle Scholar
  6. 6.
    Ching LJC, Sandler LM, Kraenzlin ME, Burrin JM, Joplin GF, Bloom SR. Long-term treatment of acromegaly with a long-acting analogue of somatostatin. Br Med J 1985; 290: 284.CrossRefGoogle Scholar
  7. 7.
    Lamberts SWJ, Uitterlinden P, Verschoor L, van Dongen KJ, del Pozo E. Long-term treatment of acromegaly with the somatostatin analogue SMS 201–995. N Engl J Med 1985; 313: 1576.PubMedCrossRefGoogle Scholar
  8. 8.
    Serrano-Rios M, Navascues J, Saban J, Ordonez A, Sevilla F, del Pozo E. Effect of a somatostatin analog (SMS 201–995) on insulin needs in IDDM by means of an artificial pancreas. J Clin Endocrinol Metab (in press).Google Scholar
  9. 9.
    Plewe G, Noelken G, Krause U, Beyer J, del Pozo E. Suppression of growth hormone and somatomedin C by the long-acting somatostatin analog SMS 201–995 in type I diabetes mellitus. Horm Res (in press).Google Scholar
  10. 10.
    Schade DS, Eaton RP. The controversy concerning counterregulatory hormone secretion. A hypothesis for the prevention of diabetic ketoacidosis? Diabetes 1977; 26: 596.PubMedCrossRefGoogle Scholar
  11. 11.
    Hansen AP, Johansen K. Diurnal patterns of blood glucose, serum free fatty acids, insulin, glucagon and growth hormone in normals and juvenile diabetics. Diabetologia 1970; 6: 27.PubMedCrossRefGoogle Scholar
  12. 12.
    Molnar GD, Taylor WF, Longworthy A, Fatourechi V. Diurnal growth hormone and glucagon abnormalities in unstable diabetics: studies in ambulatory-fed subjects during continuous blood glucose analysis. J Clin Endocrinol 1972; 34: 837.CrossRefGoogle Scholar
  13. 13.
    Press M, Tamborlane WV, Sherwin RS. Importance of raised growth hormone levels in mediating the metabolic derangements of diabetes. N Engl J Med 1984; 310: 810.PubMedCrossRefGoogle Scholar
  14. 14.
    Hansen AP. Abnormal serum growth hormone response to exercise in juvenile diabetics. J Clin Invest 1970; 49: 1467.PubMedCrossRefGoogle Scholar
  15. 15.
    Meek JC, Reitz RP, Bolinger RE. Plasma growth hormone response to glucocorticoids in diabetics. Proc Soc Exp Biol Med 1970; 135 (1): 123–6.PubMedGoogle Scholar
  16. 16.
    Campbell PJ, Bolli GB, Cryer Ph.E, Gerich JE. Parthenogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. N Engl J Med 1985; 312: 1473.PubMedCrossRefGoogle Scholar
  17. 17.
    Campbell PJ, Bolli GB, Gerich JE. Nasal somatostatin analogue: a practical and effective approach to treatment of the dawn phenomenon. Diabetes Research and Clinical Practice 1985; 1 (suppl): 84.Google Scholar
  18. 18.
    Scheen AJ, Krzentowski G, Castillo M, Lefebvre PJ, Luyckx AS. A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 2. Marked attenuation of the metabolic deterioration by somatostatin. Diabetologia 1983; 24: 319.PubMedCrossRefGoogle Scholar
  19. 19.
    Unger RH, Aguilar-Parada E, Muller W, Eisentraut A. Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 1970; 49: 837.PubMedCrossRefGoogle Scholar
  20. 20.
    Berelowitz M. Somatostatin-producing tumors: clinical aspects. Neuroendocrine Perspectives 1985; 4: 59.Google Scholar
  21. 21.
    Muller W, Faloona G, Unger RH. Hyperglucagonemia in diabetic ketoacidosis: its prevalence and significance. Am J Med 1973; 54: 52.PubMedCrossRefGoogle Scholar
  22. 22.
    Patton GS, Ipp E, Dobbs RE, Orci L, Vale W, Unger RH. Pancreatic immunoreactive somatostatin release. Proc Natl Acad Sci USA 1977; 74: 2140.Google Scholar
  23. 23.
    Orci L, Baetens D, Rufener C. Hypertrophy and hyperplasia of somatostatin-containing D-cells in diabetes. Proc Nati Acad Sci USA 1976; 73: 1338.CrossRefGoogle Scholar
  24. 24.
    Guillemin R, Gerich JE. Somatostatin: physiology and clinical significance. Annu Rev Med 1976; 27: 379.PubMedCrossRefGoogle Scholar
  25. 25.
    Kraenzlin ME, Wood SM, Neufeld M, Adrian TE, Bloom SR. Effect of long-acting somatostatin-analogue SMS 201–995 on gut hormone secretion in normal subjects. Experientia 1985; 41: 738.PubMedCrossRefGoogle Scholar
  26. 26.
    Gerich JE, Haymond M, Rizza R, Verdonk C, Miles G. Hormonal and substrate determinants of hepatic glucose production in man. In: Veneziale CM, ed. The regulation of carbohydrate formation and utilization in mammals. Baltimore: University Park Press, 1981.Google Scholar
  27. 27.
    Pyoeraelae K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979; 2: 131.CrossRefGoogle Scholar
  28. 28.
    Welborn TA, Wearne K. Coronary heart disease incident and mortality in Busselton with reference to glucose and insulin levels. Diabetes Care 1979; 2: 154.PubMedCrossRefGoogle Scholar
  29. 29.
    Hillson RM, Hochaday TDR, Mann JI, Newton DJ. Hyperinsulinemia is associated with development of electrocardiographic abnormalities in diabetics. Diabetes Research 1984; 1: 143.PubMedGoogle Scholar
  30. 30.
    Spinas GA, Bock A, Keller U. Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin analogue (SMS 201–995) in insulin-dependent diabetes mellitus. Diabetes Care 1985; 8: 429.PubMedCrossRefGoogle Scholar
  31. 31.
    Gomez-Pan A, Rodriguez-Arnao MD, del Pozo E. Advances in somatostatin research. In: del Pozo E, Fluckiger E, eds. Dopamine and neuroendocrine active substances. London: Academic Press, Inc., 1985.Google Scholar
  32. 32.
    Gottesman JS, Mandarino LJ, Gerich JE. Somatostatin: its role in health and disease. Spec Top Endocrinol Metab 1982; 4: 177.PubMedGoogle Scholar
  33. 33.
    Greco A, Ghirlanda G, Altomonte A, Manna R, Rebuzzi A, Bertoli A. Somatostatin and insulin infusion in the management of diabetes ketoacidosis. Horm Metab Res 1981; 13: 310.PubMedCrossRefGoogle Scholar
  34. 34.
    Gerich JE, Schultz T, Tsalikian E, Lorenzi M, Lewis S, Karam J. Clinical evaluation of somatostatin as a potential adjunct to insulin in the management of diabetes mellitus. Diabetologia 1977; 13: 537.PubMedCrossRefGoogle Scholar
  35. 35.
    Meissner C, Thurn C, Beischer W, Winkler G, Schroder K, Pfeiffer E. Antidiabetic action of somatostatin-assessed by the artificial pancreas. Diabetes 1975; 24: 988.PubMedCrossRefGoogle Scholar
  36. 36.
    Felig P, Wahren J. Somatostatin and diabetes: suppression of glucose absorption rather than stimulation of glucose disposal. Metabolism 1976; 25: 1509.PubMedCrossRefGoogle Scholar
  37. 37.
    Wahren J, Efendic S, Luft R, Hagenfeldt L, Bjorkman 0, Felig P. Influence of somatostatin on splanchnic glucose metabolism in post absorptive and 60 hours fasted humans. J Clin Invest 1977; 59: 299.PubMedCrossRefGoogle Scholar
  38. 38.
    Gerich JE, Lorenzi M, Bier D, et al. Prevention of human diabetic ketoacidosis by somatostatin: evidence for an essential role of glucagon. N Engl J Med 1975; 292: 985.PubMedCrossRefGoogle Scholar
  39. 39.
    Unger RH. Somatostatinoma. N Engl J Med 1977; 296: 998.PubMedCrossRefGoogle Scholar
  40. 40.
    Wright J, Abolfathi A, Penman E, Marks U. Pancreatic somatostatinoma presenting with hypoglycaemia. Clin Endocrinol 1980; 12: 603.CrossRefGoogle Scholar
  41. 41.
    Pipeleers D, Couturier E, Gepts W, Reynders J, Somers G. Five cases of somatostatinoma: clinical heterogeneity and diagnostic usefulness of basal and tolbutamide-induced hypersomatostatinemia. J Clin Endocrinol Metab 1983; 56: 1236.PubMedCrossRefGoogle Scholar
  42. 42.
    Gordon DA, Mill FM, Ezrin C. Acromegaly: a review of 100 cases. Can Med Assoc J 1962; 87: 1106.PubMedGoogle Scholar
  43. 43.
    Emmer M, Gordon P, Roth J. Diabetes in association with other endocrine disorders. Med Clin North Am 1971; 55: 1057.PubMedGoogle Scholar
  44. 44.
    del Pozo E, Chiodini PG, Lamberts SWJ, et al. Long-term treatment of acromegaly with the somatostatin analog SMS 201–995: report of 46 cases (submitted).Google Scholar
  45. 45.
    Lamberts SWJ, del Pozo E. The acute and long-term effects of SMS 201–995 in acromegaly. Scand J Gastroenterol (in press).Google Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • E. del Pozo
    • 1
  • S. W. J. Lamberts
    • 2
  • C. Sieber
    • 1
  • A. Gomez-Pan
    • 3
  1. 1.Clinical ResearchSandoz Ltd.BasleSwitzerland
  2. 2.Erasmus UniversityRotterdamThe Netherlands
  3. 3.Faculty of MedicineMadridSpain

Personalised recommendations